Prostamax
Prostamax is a synthetic short peptide marketed as a prostate-tissue "bioregulator" in the Khavinson organotropic-peptide tradition; it is commercially linked to the older Russian prostate-derived peptide preparation Prostatilen, but this identity is not confirmed in peer-reviewed literature and no study of Prostamax itself under this name could be located.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Prostamax is described by its manufacturer as a short peptide intended to act on prostate tissue via the same organotropic gene-regulation hypothesis used across the Khavinson peptide family. It is marketed as related to Prostatilen, an older calf-prostate-derived polypeptide complex studied in Russian urology literature for chronic prostatitis, but the two are not demonstrated to be molecularly identical, so mechanistic claims for Prostamax specifically remain inferred rather than directly established.
Typical results seen in research
No peer-reviewed study of 'Prostamax' under this brand name was found. Older, small, non-blinded Russian clinical studies of the related preparation Prostatilen reported symptomatic improvement in men with chronic prostatitis (including complicated cases with associated sexual dysfunction), but these studies predate modern trial standards, were not placebo-controlled in a rigorous modern sense, and cannot be assumed to apply directly to the distinct commercial product sold as Prostamax. Any prostate-health benefit attributed to Prostamax itself is therefore unproven.
How it’s commonly used
Prostamax is typically taken orally as a capsule or tablet, often cycled alongside other Khavinson-tradition tissue-specific bioregulators as part of a general prostate-health or longevity supplement regimen. It is used in a self-directed research/supplement context and is not an approved treatment for prostate disease.
- Urol Nefrol (Mosk) · 1991 [The use of prostatilen in treating patients with chronic prostatitis]
- Vrach Delo · 1991 [The treatment with the polypeptide preparation "Prostatilen" of patients with prostatitis complicated by a sexual functional disorder]
- Lik Sprava · 2004 [Polypeptide prostatilen in the treatment of patients with complicated prostatitis]
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.